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Optical fibre based real‑time
measurements during an LDR
prostate brachytherapy implant
simulation: using a 3D printed
anthropomorphic phantom
P. Woulfe1,3*, F. J. Sullivan4,5, L. Byrne1, A. J. Doyle6, W. Kam1,2, M. Martyn3 & S. O’Keeffe1,2
An optical fibre sensor based on radioluminescence, using the scintillation material terbium doped
gadolinium oxysulphide (Gd2O2S:Tb) is evaluated, using a 3D printed anthropomorphic phantom for
applications in low dose-rate (LDR) prostate brachytherapy. The scintillation material is embedded in a
700 µm diameter cavity within a 1 mm plastic optical fibre that is fixed within a brachytherapy needle.
The high spatial resolution dosimeter is used to measure the dose contribution from Iodine-125
(I-125) seeds. Initially, the effects of sterilisation on the sensors (1) repeatability, (2) response as a
function of angle, and (3) response as a function of distance, are evaluated in a custom polymethyl
methacrylate phantom. Results obtained in this study demonstrate that the output response of
the sensor, pre- and post-sterilisation are within the acceptable measurement uncertainty ranging
from a maximum standard deviation of 4.7% pre and 5.5% post respectively, indicating that the low
temperature sterilisation process does not damage the sensor or reduce performance. Subsequently,
an LDR brachytherapy plan reconstructed using the VariSeed treatment planning system, in an
anthropomorphic 3D printed training phantom, was used to assess the suitability of the sensor for
applications in LDR brachytherapy. This phantom was printed based on patient anatomy, with the
volume and dimensions of the prostate designed to represent that of the patient. I-125 brachytherapy
seeds, with an average activity of 0.410 mCi, were implanted into the prostate phantom under transrectal ultrasound guidance; following the same techniques as employed in clinical practice by an
experienced radiation oncologist. This work has demonstrated that this sensor is capable of accurately
identifying when radioactive I-125 sources are introduced into the prostate via a brachytherapy
needle.
A common treatment option for prostate cancer is low dose rate (LDR) seed brachytherapy, which has been
shown to have excellent long-term o
 utcomes1. The main advantage of the technique is its use of a higher dose
of radiation in a more targeted area, compared with external beam radiotherapy2. A real-time intraoperative
guided trans-perineal LDR prostate brachytherapy technique, popularized by Stone and Stock3, is employed in
this work. Good technique is required to ensure optimal dosimetry, and acceptable short as well as long term
outcomes3. Trans-rectal ultrasound (TRUS) guidance is utilised during implantation to visualise the prostate and
surrounding anatomy, and to guide the insertion of needles, through which brachytherapy seeds are delivered.
TRUS imaging provides excellent soft tissue visualisation, making it ideal for applications in the treatment of
prostate cancer. However, due to the limited spatial resolution of ultrasound (US) transceivers, and due to the
low echogenic nature of metallic seeds, the identification of seed locations is often d
 ifficult4. Accurate knowledge
of implanted seed location is crucial when assessing adherence to the employed dosimetric criteria; ensuring
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Figure 1.  Optical fibre based radiation dosimeter: (a) schematic of sensor design, (b) optical fibre sensor within
brachytherapy needle in the sterilized packages.
adequate dose to the prostate ( D90, V100, V150), while also minimising dose to the organs at risk ( D30 urethra, as
well as D2cc rectum), in line with international guidelines5.
The aim of this study is to perform in vitro measurements using an optical fibre based sensor, in a 3D printed
anthropomorphic phantom. This work therefore acts as a proof of concept for ultimately employing an optical fibre based system for real time in vivo dosimetry (RTIVD); enabling treatment interruption if measured
doses [derived from the photon counting rate (PCR)] differ significantly from the treatment plan. An optical
fibre based system employed in this way could be used as a radiation protection tool and as a treatment quality
assurance (QA) tool. Measurements are limited only by the accuracy of the dosimeter and the knowledge of its
position within the patient6.

Materials

I‑125 source. The seeds used in LDR brachytherapy, within our clinical setting, are typically Iodine-125
(I-125), with a half-life of 59.43 days. Once again, within our clinical setting, typical apparent activities employed
range from 0.357 to 0.42 mCi, and the typical number of seeds employed range from 60 to 80 seeds, depending
on the volume of the prostate. Theragenics Co., I-Seed I-125, AgX100 were used in the present study. Source
dimensions for the AgX100 seeds are detailed in Mourtada et al7. The mean photon energy on the surface of
an AgX100 seed has been calculated as 27.29 keV in the Carleton Laboratory for Radiotherapy Physics (CLRP)
TG-43 parameter database, with statistical uncertainties < 0.01%8.
Terbium doped gadolinium oxysulphide optical fibre dosimeter. The optical fibre sensor, shown in
Fig. 1a, is constructed by micromachining a cavity in the 1 mm core of a polymethyl methacrylate (PMMA) plastic optical fibre. The cavity, 700 μm in diameter and 7 mm in depth, is filled with a scintillating material, terbium
doped gadolinium oxysulphide (Gd2O2S:Tb, GOS) and sealed with a Henkel Loctite Hysol M-31CL Medical
Device Epoxy. The scintillation material fluoresces on exposure to ionising radiation and the resultant emitted
fluorescent light penetrates the PMMA optical fibre core and propagates along the fibre to a Hamamatsu MultiPixel Photon Counting Module (MPPC) C133669 for monitoring of the optical signal. The data was captured
using proprietary software of the MPPC with a gate time setting of 100 ms and 0.5 photo-electron threshold. The
gate time represents the time duration within which the photon counts are integrated, within the MPPC module.
The data presented in this work is the optical signal captured in the presence of an I-125 seed, minus the dark
count rate (DCR) captured at near zero light input. The small dimensions of the s ensor10,11, with an overall outer
diameter of 1 mm, allow for it to be guided within existing brachytherapy equipment (e.g. within the brachytherapy needle), as shown in Fig. 1b. This will allow the sensor to be located directly within the prostate, using
techniques the radiation oncologist is already familiar with.
Sterilization. The STERRAD® NX System12 developed by Advanced Sterilization Products (ASP), a Johnson
& Johnson company, uses both hydrogen peroxide vapor and low-temperature gas plasma to rapidly sterilize
the dosimeters. Since the load temperatures do not exceed 55 °C and sterilization occurs in a low moisture
environment, the STERRAD® NX System is particularly suited to the sterilization of heat and moisture-sensitive
instruments. The process that occurs is as follows: the dosimeter to be sterilized is placed in the sterilization
chamber, the chamber is closed, aqueous hydrogen peroxide is delivered to the vaporizer/condenser, and evacuation begins. The overall sterilization process was repeated twice. Figure 1b above depicts the sterilized dosimeters packaged for use.
Phantoms. Two phantoms were utilised during the course of this evaluation. The first, a custom PMMA
(also known as Lucite, Plexiglas or Perspex) phantom was used to evaluate the effects of the sterilisation process
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Figure 2.  Phantoms used during sensor evaluation: (a) PMMA Phantom, (b) 3D printed anthropomorphic
phantom.
on the sensor response. The second, an anthropomorphic 3D printed training phantom, was used to validate the
sensor for RTIVD.
PMMA Phantom. This PMMA Phantom, shown in Fig. 2a, has a density of 1180 kg m−3, and was used to
evaluate the effect of the sterilisation process on the optical fibre sensor. The phantom design has outer dimensions of 80 × 80 × 90 mm3, created from 10 mm thick slabs stacked together, and a central hole to accommodate
the dosimeter. An array of 13 × 13 holes, each with a diameter of 1 mm, were machined to replicate a prostate
biopsy template used in LDR Brachytherapy. To provide full scatter conditions, the I-125 source was surrounded
by a sufficient amount of phantom m
 aterial13. Thus, during irradiation, the PMMA sheet containing the I-125
sources and optical fibre were contained between four further sheets of PMMA, resulting in a depth of 4 cm. A
90 mm thick phantom is considered to offer adequate backscatter for low energy brachytherapy sources as we
have seen range of detection limited to 30 mm14. During irradiation, the longitudinal axes of both the sensor and
the I-125 seed are parallel, with their centres aligned.
Anthropomorphic 3D printed training phantom. This paper also utilises an anthropomorphic, 3D printed training phantom for LDR brachytherapy for prostate cancer, described by Doyle et al15,16. In contrast to those found
commercially, this phantom can be used to plan and validate treatment tailored to an individual patient. The
phantom, shown in Fig. 2b was used as a test bed for the optical fibre sensor. The high-fidelity phantom replicated the soft tissue characteristics of the male pelvis and facilitated needle puncture and the introduction of
both I-125 seeds and the optical fibre sensor contained within a brachytherapy needle. The sensor is introduced
through the brachytherapy needle grid to monitor in real-time the photon count rate (PCR) during the procedure.

Methods

Testing was performed at the Radiotherapy Department, Galway Clinic, Galway. The first of these experiments
was to examine the performance of the dosimeter pre-sterilisation versus post-sterilisation by investigating the
following: (1) Repeatability, (2) response as a function of angle, and (3) response as a function of distance to
demonstrate sensitivity. This work was carried out to identify any issues relating to the sterilisation process on
the sensor performance, prior to the evaluation of the sensor for in vitro measurements using the anthropomorphic phantom.
The optical fibre dosimeter was fixed within the central hole of the PMMA Phantom at a depth of 4 cm as
depicted in Fig. 2a. The brachytherapy seeds were inserted into the PMMA Phantom for a fixed period of time
and the response of the sensor was monitored. The phantom set-up was designed such that the centres of the
radiation source and the optical fibre sensor were aligned. The sensor was initially tested for its response to one
0.410 mCi I-125 seed, for a comparison of optical signal, pre/post-sterilisation. In this particular investigation,
the repeatability of the sensor was evaluated by removing and re-introducing the sensor over three consecutive
cycles at a distance of 5 mm (± 1 mm positional uncertainty) from the radiation source. The second investigation
sought to assess the response of the optical fibre sensor (OFS) as a function of angle with respect to the seed,
which was again positioned 5 mm from the sensor. Four angles were evaluated, along the plane perpendicular to
the centre of the sensors longitudinal axis; 0° (Top), 90° (Right), 180° (Bottom) and 270° (Left). Finally, we examine the sensitivity of the sensor as a function of distance from a single seed, over the range 5–30 mm, in 5 mm
steps. The dose fall-off with distance from the radiation source can be described using the TG-43 f ormulism13,
via the VariSeed (Varian Medical Systems) treatment planning system (TPS) [Version 8.0.2], and compared to
the photon counting rate (PCR) fall-off measured with the sensor. Each of the investigations described above
were performed with the sensor pre-sterilisation and post-sterilisation.
For the second part of the study, a realistic clinical prostate brachytherapy case was simulated using a 3D
printed training phantom, this phantom was printed based on patient anatomy with exact volume and dimensions
of the prostate to represent the patient. One of the authors (FS), an experienced radiation oncologist, performed
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Figure 3.  3D anthropomorphic phantom treatment plan in the VariSeed TPS. Post-implant dosimetry analysis
displaying transverse, longitudinal, and coronal views (without live video signal): I-125 seeds (green), prostate
(red), urethra (yellow), and isodose lines are displayed.

the simulation using exactly the same techniques employed in clinical practice17. A Hitachi Preirus (Hitachi
Medical Solutions) US system was used to acquire the images of the 3D printed training phantom. Steps involved
in the simulation process were setting the prostate symmetrically within the grid, identifying the base of the
prostate on sagittal imaging, identifying the apex of the prostate on both sagittal and axial imaging, determining
the length and volume of the prostate, and acquiring the images required for treatment planning by using a 5 mm
stepping device (Civco Inc). Images are captured within the VariSeed TPS via a direct link with the US system.
During the implant procedure, 3–4 seeds were evenly spaced throughout the length of the simulated prostate
for each needle (see Fig. 3), to achieve the desired dosimetric coverage (50 peripheral seeds were implanted in
total). The entire implantation procedure was recorded and a timestamp was assigned to each seed to provide
accurate time correlation with the real-time photon counting rate (PCR) from the sensor.
Within the VariSeed TPS, shown in Fig. 4, a structure was added at a position corresponding to C2.5 on
the template grid to represent the position of the sensor (blue cylinder). This cylindrical sensor structure has
a diameter of 2 mm (accounting for the 1 mm outer diameter of the optical fibre and a positional uncertainty
of approximately ± 1 mm) and a length of 5 mm (dictated by the 5 mm slice spacing employed during image
acquisition). Figure 4 also provides a representation of the position and distribution of the implanted I-125
seeds (green)/needles with respect to the sensor. Using VariSeed the “expected” dose to the sensor structure was
calculated for each of the 50 seeds that were inserted into the periphery of the prostate. This allows for a relative comparison of the “accumulated dose” to the sensor structure, within the TPS, and the real-time PCR from
the sensor, as a function of time. The data presented in this work represent the PCR minus the dark count rate
(background noise). The objective of this work was to identify if the sensor was capable of accurately identifying
when radioactive I-125 sources were introduced into the simulated prostate for each peripheral needle (i.e. is
there a noticeable increase in the PCR per needle).

Results

Sterilisation effects. The average PCR pre- and post-sterilisation was 1290 and 1307 counts per gate (c.p.g.)
respectively (above the DCR of approximately 1100 c.p.g); these figures represent the average of the mean PCR
for each individual measurement, integrated over 170 s. The pooled standard deviation (SD) of the PCR pre- and
post-sterilisation are 59 and 69 c.p.g. respectively; where the pooled SD is defined as the root mean square of
the standard deviations for each individual measurement, integrated over 170 s. The response of the sensor as a
function of angle with respect to the radiation source are presented in Table 1. PCR measurements acquired at
each angle agree within measurement uncertainty (defined by the SD), both pre- and post- sterilisation.
PCR fall-off as a function of distance was also considered with the results illustrated in Fig. 5. Based on the
findings of the repeatability measurements, measured data in Fig. 5 represent the average of the PCR signal
obtained with the sensor both pre and post sterilization, since the sterilization process has been shown to have
no significant impact on the measurement signal. PCR data were integrated over a period of 130 s, at each given
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Figure 4.  (a) Coronal view of structures/sources in VariSeed TPS: sensor (blue cylinder), prostate (red),
urethra (yellow), and I-125 seeds (green). (b) Transverse view of structures / sources with needle numbers also
identified.

Pre-sterilisation

Post-sterilisation

Angle

Mean (c.p.g.)

SD (c.p.g.)

SD (%)

Mean (c.p.g.)

SD (c.p.g.)

SD (%)

Top—0°

1323

61

4.6

1368

60

4.4

Bottom—180°

1274

62

4.9

1239

70

5.6

Right—90°

1294

58

4.5

1232

60

4.9

Left—270°

1294

70

5.4

1229

71

5.8

Table 1.  Mean and SD of the PCR for each angle considered.

OFS Measurement

TPS

1600

y = 79321x-2.279
R² = 1

Photon Count Rate (c.p.g.)
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Figure 5.  Average PCR measurement data (black circles) as a function of distance from a single I-125 seed
obtained pre- and post-sterilisation. Theoretical data generated using the VariSeed TPS (red circles) are
normalised to the PCR measurement value at 10 mm. The dashed red line represents a power trendline fit to the
theoretical data, with the equation of the line shown in the top right corner of the graph in red text.
distance, for both the pre and post sterilization measurements. The vertical error bars on the measurement data
represent the pooled SD of the PCR (multiplied by two for 95% confidence), integrated over a period of 130 s,
at each distance. The horizontal error bars on the measurement data represent a ± 1 mm positional uncertainty.
The expected dose fall-off rate was calculated using the VariSeed TPS, for the AgX100 seed, with anisotropy correction performed using anisotropy factors (geometry factor point source approximation). These TPS settings
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Figure 6.  Photon count rate (primary vertical axis) and Absorbed Dose (secondary vertical against) plotted as
a function of time, over the course of an I-125 implantation procedure in a 3D anthropomorphic phantom. The
real-time PCR data are displayed as black dots, expected absorbed dose readings from the TPS are displayed as
solid red circles (one per implanted seed), and vertical grey lines represent each of the 13 peripheral needles.

reflect those employed clinically in the Galway Clinic. Figure 5 shows a comparison of sensor measurements
with TPS expectation.

3D phantom LDR Brachy simulated implant.

Accumulated dose to the sensor structure, calculated
in the VariSeed TPS, and the real-time PCR data from the sensor, as a function of time are presented in Fig. 6.
Accumulated dose values represent the mean dose to the sensor structure in VariSeed, per implanted seed, with
“error bars” in this case simply illustrating the minimum and maximum dose values within said structure. The
minimum and maximum dose values are displayed in this way to give the reader a representation of the steep
dose gradients involved in brachytherapy dosimetry and to illustrate the effect that positional uncertainty can
have on measured photon counts.

Discussion

During the repeatability study, repeated measurements required the sensor to be removed from the phantom
prior to each individual measurement, introducing an element of variability due to the repositioning of the sensor
on re-insertion within the phantom, relative to the I-125 seed. However, results obtained in this study demonstrate that the output response of the sensor, pre- and post- sterilisation are within the acceptable measurement
uncertainty ranging from a maximum standard deviation of 4.7% pre and 5.5% post respectively, indicating
that the low temperature sterilisation process does not damage the sensor or reduce performance. Furthermore,
analysis of sensor measurements obtained at four angles with respect to the radiation source agree within measurement uncertainty, indicating sensor response uniformity.
Figure 5 shows that the rate of change of the PCR, as a function of distance, is well described by the TG-43
formulism, via the VariSeed TPS, within measurement uncertainty. Within the range of distances considered in
this work, the PCR fall-off is dominated by the inverse square law. Furthermore, Fig. 5 illustrates the impact of
positional uncertainty on the accuracy of the acquired output measurement, particularly as distance decreases,
due to the steep dose gradient. This represents a key challenge when it comes to accurately measuring the dose
distribution close to brachytherapy sources. Future work and further development of the optical fibre based
system and measurement processes will aim to continue to reduce this positional uncertainty, so as to address
this challenge. For example, for the purposes of optical fibre sensor characterisation, replacing the solid PMMA
phantom with a watertank would allow for more precise positioning of the sensor with respect to the radiation
source. Furthermore, when considering the ultimate goal of transferring this technology to the clinical setting
for in vivo patient measurements, it is envisaged that an external tracking system could be implemented, which
would allow for precise localisation of implanted sensors within the patient.
From Fig. 6, it is clear that the output signal from the sensor and the expected dose calculated by the TPS initially rise quickly (Needles 1–3), followed by a period of relatively slow increase in PCR/absorbed dose (Needles
4–12), before finally showing a sharp rise again for the final peripheral needle (Needle 13). This behaviour can
be explained when one considers the position of the radiation sources (I-125 seeds) with respect to the position
of the sensor. As shown in Fig. 5, the PCR falls off quickly with distance.
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What can also be seen in Fig. 6 is that in the regions of the steepest dose gradients, the measured PCR seems
to under-estimate the expected accumulated dose to the sensor position. It is hypothesised that the observed
disagreement between real-time PCR and accumulated dose in these regions is likely due to the angular dependence of the sensor along the longitudinal plane (i.e. the sensor geometry is cylindrically symmetrical so changes
in response along the longitudinal plane can be expected) and/or anisotropy in the dose distribution along the
longitudinal plane. Future work will consider further characterisation of angular dependence for both polar
and azimuthal angles.
For the purposes of this work, however, the objective was to identify if the sensor was capable of accurately
identifying when radioactive I-125 sources were introduced into each peripheral needle. When the needles are
close to the sensor (≤ approximately 20 mm) it is clear from Fig. 6 that this objective is fulfilled; where sharp rises
in PCR are observed at points which correlate with timestamps for the implantation of seeds in a new needle
(Needles 1–3 and Needle 13). Where needles are further away from the sensor however, relative increases in the
PCR are much smaller, making it difficult to discern the implantation of seeds through a new needle (needles
4–12). This result suggests that future work may consider the implantation of multiple sensors to overcome this
limitation. The authors suggest using multiple sensors, as opposed to moving a single sensor for example, since
the precision with which the position of the sensor(s) are known is critical to the overall accuracy of the system.
Therefore sensors will be positioned and localised at the beginning of a procedure and will remain in position
throughout the clinical case, to ensure positional uncertainties are minimised.
Future work will consider characterisation of any energy dependence for the sensor employed in this study
and its influence on the conversion process from PCR (c.p.g.) to dose rate (cGy h−1). It is worth noting however
that previous Monte Carlo modelling work by Meigooni et al18 and Weaver et al19 have demonstrated that changes
in the energy spectra for Iodine 125 are small over the distance range considered, indicating that a correction
for energy as a function of distance may not be necessary. The finding presented in this work, is that the fall-off
in the PCR as a function of distance agrees with expectation from the TG-43 formulism, seems to be in agreement with this indication.

Conclusion

Results obtained in this study demonstrate that the output response of the sensor, pre- and post- sterilisation is
within the acceptable measurement uncertainty, indicating that the sterilisation process does not damage the
sensor or reduce performance. A real time intraoperative LDR prostate brachytherapy treatment in a simulated
prostate, using a novel 3D printed anthropomorphic phantom, was performed. Optical fibre measurements
demonstrated that the system is capable of accurately identifying when radioactive I-125 sources are introduced
into a needle, when the needles are close to the sensor (≤ approximately 20 mm). Future work and areas for
further development have also be identified and discussed in this study (e.g. minimising positional uncertainty,
further characterisation of angular dependence, and the possible use of a multi-sensor configuration for in vivo
measurements, and characterisation of energy dependence).
In the opinion of the authors this study demonstrates the potential of this GOS based optical fibre dosimetry
system to be employed as an RTIVD tool, during an LDR prostate brachytherapy implantation procedure. It is
minimally invasive, providing additional valuable dosimetry information which will aid the radiation oncologist, ensuring optimum seed placement and good long term clinical outcomes. We believe this system has the
potential for further investigation in clinical brachytherapy practice.
Received: 15 October 2020; Accepted: 17 May 2021
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